The Effect Of Aspirin On Platelet Activation Markers And The Preliminary Study Of Aspirin Resistance In Patients With Coronary Heart Disease

Objective:1. To observe the effect of aspirin on platelets activation markers in patients withcoronary heart disease.2. To set up the diagnostic criteria of aspirin resistance.3. To preliminary predict the incidence of aspirin resistance in hospital patients.Methods:The subjects were divided into 3 groups: aspirin group (103 cases), control group(24 cases), and healthy control group (23 cases) for comparison. Using whole bloodsamples, We detected the ratio of CD62P, PAC-1 expression with flow cytometry(FCM) before and after 7-day treatment and compared the changes of CD62P andPAC-1 expression ratio, then calculate the inhibition ratio of platelets glycoprotein,set up the diagnostic criteria of Aspirin Resistance with Receiver operatorcharacteristic curve (ROC) and calculate the incidence of aspirin resistance inhospital patient.Results:1. Compared to healthy control group (CD62P: 2.28±1.63,PAC-1: 2.42±1.47),The platelet CD62P and PAC-1 expression in CHD group (CD62P: 6.67±5.63%,PAC-: 14.33±10.491%) is statistically higher than controlgroup(P＜0.01). 2. There was no difference before treatment in the expressions of CD62P andPAC-1, but significant statistical difference after different treatment (P＜0.05)between aspirin group and control group. The statistical results is listed as below:in aspirin group, before treatment CD62P: 10.16±6.80%, PAC-1: 14.66±10.56,and after treatment CD62P: 5.70±4.28,PAC-1: 8.93±7.08, P＜0.01. In controlgroup, before treatment CD62P: 9.14±6.52%,PAC-1: 17.67±11.53%, and aftertreatment CD62P: 7.81±5.72%,PAC-1: 14.97±8.05%,P＜0.05.3. According to ROC, the inhibition ratio of CD62P＜21.5%or PAC-1＜17.7%wasindividually set up as diagnostic criteria of AR. Our study indicated that Theincidence of Aspirin Resistance in hospital CHD patients is 17.5%.Conclusions:1. There exists platelet activation in CHD patients. CD62P and PAC-1 could beconsidered as the sensitive index of platelet activation and be used in theevaluation of anti-platelet therapy.2. Aspirin can decrease the expressions of CD62P and PAC-1, and inhibit theactivation of platelet.3. Aspirin Resistance exists in CHD patients and the incidence of AR in hospitalCHD patients. By FCM, the diagnostic criteria of Aspirin Resistance in CHD isthe inhibition ratio of CD62P＜21.5% or PAC-1＜17.7% due to using aspirin. Theincidence of Aspirin Resistance in hospital CHD patients is 17.5%.